SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs about clarification

04 Aug 2025 Evaluate
GlaxoSmithKline Pharmaceuticals has informed that in reference to the communications dated August 1, 2025 received from National Stock Exchange of India, bearing reference number: NSE/CM/Surveillance/15703, and from BSE Limited, bearing reference number: L/SURV/ONL/RV/AJ/ (2025-2026)/ 54, seeking clarification regarding the news article published on https://www.moneycontrol.com on August 1, 2025, titled 'Trump Tariff News Live: GSK and AstraZeneca among top companies told to 'cut US prices or else'. At the outset, it is clarified that the said news item does not pertain to GlaxoSmithKline Pharmaceuticals (the Company). Instead, it concerns GSK plc (previously GlaxoSmithKline plc), our ultimate parent company in the United Kingdom. The Company does not have any further information regarding the events stated in the said article and is therefore unable to comment on any material impact of the same on the Company. The Company is also not aware of any information or announcement, including any pending announcement, which in the Company’s opinion, could have a bearing on the share price of the Company. Accordingly, at present, the Company does not have any information concerning the events stated in the said article which is disclosable in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2409.85 16.60 (0.69%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×